Basket cover image
17 handpicked stocks

Lottery Tickets

These visionary companies are betting it all on game-changing innovations that could revolutionize entire industries. Hand-selected by our analysts, each represents a high-risk, high-reward opportunity with potential for explosive growth if their breakthrough technologies succeed.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+7

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at जून 17

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

OKLO

ALTC ACQUISITION CORP-CL A

OKLO

Current price

$65.41

The company is developing innovative small modular nuclear reactors, a groundbreaking but not yet commercialized energy technology.

SPCE

Virgin Galactic Holdings Inc

SPCE

Current price

$2.97

It represents a pure-play investment in the high-risk, unproven market of commercial space tourism.

RXRX

RECURSION PHARMACEUTICALS-A

RXRX

Current price

$5.09

This company is leveraging a speculative, AI-driven platform to industrialize drug discovery, a high-potential but currently unprofitable model.

About This Group of Stocks

1

Our Expert Thinking

These companies are united by their focus on potentially revolutionary technologies that haven't yet proven commercially viable. They represent high-risk, high-reward bets on transformative ideas in fields like gene editing, clean energy, spaceflight, and AI-driven drug discovery.

2

What You Need to Know

These stocks are highly speculative and often pre-revenue, meaning they're banking everything on a single breakthrough technology. They're best viewed as a small portion of a diversified portfolio, offering the possibility of explosive growth if their core innovation succeeds.

3

Why These Stocks

Our analysts selected these companies based on their significant intellectual property, disruptive potential, and novel approaches to solving big problems. Recent increases in venture funding for frontier technologies and evolving regulations are creating favorable conditions for these innovations.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+440.75%

Group Performance Snapshot

440.75%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 440.75% over the next year.

14 of 17

Stocks Rated Buy by Analysts

14 of 17 assets in this group are rated Buy by professional analysts.

1.9%

Group Growth

This group averaged a 1.9% return last month.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🚀

Moonshot Potential

These companies could deliver explosive returns if their revolutionary technologies succeed commercially. One breakthrough announcement could send share prices soaring.

🔬

Tomorrow's Breakthroughs Today

Get early access to cutting-edge innovations that could transform entire industries, from nuclear energy and space tourism to gene editing and AI-powered medicine.

💡

Backed by Brilliant Minds

These visionary companies are led by some of the boldest thinkers and innovators in their fields, betting everything on ideas that could change the world.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.